Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 7/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30091780 | 1.00 | EGFR (0.43) | EGFRBTKF10ACACBRXRA | |
| SCHEMBL30091779 | 0.83 | MGLL (0.53) | EGFRBTK | |
| SCHEMBL22400934 | 0.83 | EGFR (0.44) | EGFRBTKACACBRXRAGRIN1 | |
| SCHEMBL22405034 | 0.83 | MGLL (0.53) | EGFRBTK | |
| SCHEMBL30313904 | 0.83 | EGFR (0.44) | EGFRBTKACACBRXRAGRIN1 | |
| SCHEMBL22404959 | 0.82 | ACACB (0.43) | EGFRBTKF10ACACBDYRK1A | |
| SCHEMBL30091809 | 0.82 | ACACB (0.43) | EGFRBTKF10ACACBDYRK1A | |
| SCHEMBL22405002 | 0.81 | EGFR (0.43) | EGFRBTKF10ACACBRXRA | |
| SCHEMBL22404979 | 0.81 | ENPP2 (0.57) | EGFRBTKDYRK1A | |
| SCHEMBL22534775 | 0.81 | MEN1 (0.43) | EGFRBTKF10RXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | EGFR 403/4885BTK 1/4885F10 2180/4885 |
| US-11542249-B2 | BTK inhibitor compounds | BTK, SYK, LCK | EGFR 380/4885BTK 1/4885F10 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.